• metastatic/advanced hepatocellular cancer (mHCC)
• mHCC - (neo)adjuvant (NA)
• mHCC - 1st line (L1) 4
• mHCC - 2nd line (L2) 2
• lung cancer : non small cell (NSCLC) 5

 

• gene alteration target therapy
• BRAF gene alteration targeted therapy
• BRAF inhibitor
• combined BRAF-MEK inhibitors
• trametinib plus dabrafenib
• KRAS gene alteration targeted therapy
• sotorasib
• MET gene alteration targeted therapy
• capmatinib
• NTRK gene alteration targeted therapy
• entrectinib
• larotrectinib
• RET gene alteration targeted therapy
• pralsetinib
• selpercatinib
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab plus SoC
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus carboplatin plus paclitaxel
• atezolizumab plus pemetrexed and platin
• avelumab based treatment
• avelumab alone
• cemiplimab
• durvalumab based treatment
• durvalumab alone
• durvalumab plus osimertinib
• nivolumab based treatment
• nivolumab alone
• nivolumab plus SoC
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (2mg/kg)
• pembrolizumab and pemetrexed plus platin
• pembrolizumab plus SoC
• sintilimab based treatment
• sintillimab plus SoC
• Tislelizumab
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC
• pembrolizumab plus ipilimumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs nucleoside analogues (pyrimidine/purine)
• vs gemcitabine
• vs taxanes
• vs docetaxel
• vs paclitaxel
• vs nab-paclitaxel
• vs vinca alkaloids
• vs vinorelbine
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs gemcitabine plus platin
• vs paclitaxel plus carboplatin
• vs carboplatin plus nab-paclitaxel
• vs pemetrexed plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs gene alteration target therapy
• vs ALK inhibitors
• vs crizotinib
• vs EGFR gene alteration
• vs osimertinib
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs atezolizumab based treatment
• vs atezolizumab plus carboplatin plus nab-paclitaxel
• vs pembrolizumab based treatment
• vs pembrolizumab alone
• vs pembrolizumab (10mg/kg)
• vs pembrolizumab plus placebo
• vs pembrolizumab plus SoC
• vs non active control
• vs no additional treatment
• vs no control (uncontrolled study)
• vs placebo
• vs placebo plus BSC
• vs VEGF(R) inhibitor
• vs bevacizumab based treatment
• vs bevacizumab plus carboplatin and paclitaxel

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  mNSCLC - L1 - all population;